Acute Lymphoblastic Leukemia Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Jan 2019| TMR1300A| Transparency

Report Highlights

Global Acute Lymphoblastic Leukemia Market: Overview

This report analyzes the current and future scenario of the global acute lymphoblastic leukemia market. Increase in patient population with acute lymphoblastic leukemia, expansion of the pharmaceutical industry, improvement in health care infrastructure, and increase in the number of clinical trials are projected to be major drivers of the global market during the forecast period.

The global acute lymphoblastic leukemia market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on treatment, type, end-user, and region. A detailed qualitative analysis of drivers and restraints of the market, and opportunities has been provided in the overview section. Additionally, the section comprises competitive matrix and company profiles along with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global acute lymphoblastic leukemia market.

Global Acute Lymphoblastic Leukemia Market: Key Segments

In terms of type, the global acute lymphoblastic leukemia market has been classified into B-cell and T-cell. Based on treatment, the global acute lymphoblastic leukemia market has been segregated into chemotherapy, radiation therapy, bone marrow transplant, targeted therapy, and immunotherapy. The segments have been analyzed based on available drug product used during the treatment of acute lymphoblastic leukemia, cost-effectiveness, and preference for industries. In terms of end-user, the global market has been divided into hospitals, clinics, and others. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.

Global Acute Lymphoblastic Leukemia Market: Regional Outlook

In terms of region, the global acute lymphoblastic leukemia market has been segmented into North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, Israel, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in Report

The report also profiles major players in the global acute lymphoblastic leukemia market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in the market report include Sanofi, Pfizer, Novartis AG, F. Hoffmann-La Roche Ltd., Erytech Pharma Inc., Celgene Corporation, Amgen, Inc. Bristol-Myers Squibb Company, and Spectrum Pharmaceuticals, Inc.

The global acute lymphoblastic leukemia market has been segmented as below:

Global Acute Lymphoblastic Leukemia Market, by Type
B-cell
T-cell
Global Acute Lymphoblastic Leukemia Market, by Treatment
Chemotherapy
Radiation Therapy
Bone Marrow Transplant
Targeted Therapy
Immunotherapy
Global Acute Lymphoblastic Leukemia Market, by End-user
Hospitals
Clinics
Others
Global Acute Lymphoblastic Leukemia Market, by Region
North America
U.S.
Canada
Europe
Germany
U.K.
Italy
France
Spain
Rest of Europe
Asia Pacific
India
China
Japan
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Israel
Rest of Middle East & Africa

  • Table 1 : Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Type, 2016–2026
  • Table 2 : Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Treatment, 2016 – 2026
  • Table 3 : Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by End-user, 2016–2026
  • Table 4 : Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Region, 2016–2026
  • Table 5 : North America Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Country,
  • Table 6 : North America Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Type,
  • Table 7 : North America Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Treatment, 2016–2026
  • Table 8 : North America Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by End-user, 2016 – 2026
  • Table 9 : Europe Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Country/Sub-region,
  • Table 10 : Europe Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Type,
  • Table 11 : Europe Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Treatment, 2016–2026
  • Table 12 : Europe Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by End-user, 2016 – 2026
  • Table 13 : Asia Pacific Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Table 14 : Asia Pacific Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Type,
  • Table 15 : Asia Pacific Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Treatment, 2016–2026
  • Table 16 : Asia Pacific Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by End-user, 2016 – 2026
  • Table 17 : Latin America Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Country/Sub-region,
  • Table 18 : Latin America Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Type,
  • Table 19 : Latin America Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Treatment, 2016–2026
  • Table 20 : Latin America Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by End-user, 2016 – 2026
  • Table 21 : Middle East & Africa Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Table 22 : Middle East & Africa Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Type,
  • Table 23 : Middle East & Africa Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Treatment, 2016–2026
  • Table 24 : Middle East & Africa Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by End-user,
  • Figure 1 : Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, 2016–2026
  • Figure 2 : Global Acute Lymphoblastic Leukemia Market Value Share (%), by Type (2017)
  • Figure 3 : Global Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment (2017)
  • Figure 4 : Global Acute Lymphoblastic Leukemia Market Value Share (%), by End-user (2017)
  • Figure 5 : Global Acute Lymphoblastic Leukemia Market Value Share (%), by Region (2017)
  • Figure 6 : Global Acute Lymphoblastic Leukemia Market Value Share (%), by Type, 2018 and 2026
  • Figure 7 : Global Acute Lymphoblastic Leukemia Market Attractiveness, by Type, 2018–2026
  • Figure 8 : Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by B-cell
  • Figure 9 : Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by T-cell
  • Figure 10 : Global Acute Lymphoblastic Leukemia Market Value Share Analysis, by Treatment, 2018-2026
  • Figure 11 : Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by Chemotherapy
  • Figure 12 : Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by Radiation Therapy, 2016–2026
  • Figure 13 : Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by Bone Marrow Transplant
  • Figure 14 : Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by Targeted Therapy, 2016–2026
  • Figure 15 : Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by Immunotherapy, 2016–2026
  • Figure 16 : Global Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Treatment, 2018-2026
  • Figure 17 : Global Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
  • Figure 18 : Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by Hospitals
  • Figure 19 : Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by Clinics, 2016–2026
  • Figure 20 : Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2016–2026
  • Figure 21 : Global Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018–2026
  • Figure 22 : Global Acute Lymphoblastic Leukemia Market Value Share Analysis, by Region, 2018 and 2026
  • Figure 23 : Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Region, 2018-2026
  • Figure 24 : North America Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
  • Figure 25 : North America Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country, 2018 and 2026
  • Figure 26 : North America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country, 2018–2026
  • Figure 27 : North America Acute Lymphoblastic Leukemia Market Value Share Analysis, by Type, 2018 and 2026
  • Figure 28 : North America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Type, 2018–2026
  • Figure 29 : North America Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2018 and 2026
  • Figure 30 : North America Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2018–2026
  • Figure 31 : North America Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
  • Figure 32 : North America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018-2026
  • Figure 33 : Europe Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
  • Figure 34 : Europe Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
  • Figure 35 : Europe Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
  • Figure 36 : Europe Acute Lymphoblastic Leukemia Market Value Share Analysis, by Type, 2018 and 2026
  • Figure 37 : Europe Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Type, 2018–2026
  • Figure 38 : Europe Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2018 and 2026
  • Figure 39 : Europe Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2018–2026
  • Figure 40 : Europe Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
  • Figure 41 : Europe Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018-2026
  • Figure 42 : Asia Pacific Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
  • Figure 43 : Asia Pacific Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
  • Figure 44 : Asia Pacific Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
  • Figure 45 : Asia Pacific Acute Lymphoblastic Leukemia Market Value Share Analysis, by Type, 2018 and 2026
  • Figure 46 : Asia Pacific Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Type, 2018–2026
  • Figure 47 : Asia Pacific Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2018 and 2026
  • Figure 48 : Asia Pacific Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2018–2026
  • Figure 49 : Asia Pacific Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
  • Figure 50 : Asia Pacific Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018-2026
  • Figure 51 : Latin America Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
  • Figure 52 : Latin America Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
  • Figure 53 : Latin America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
  • Figure 54 : Latin America Acute Lymphoblastic Leukemia Market Value Share Analysis, by Type, 2018 and 2026
  • Figure 55 : Latin America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Type, 2018–2026
  • Figure 56 : Latin America Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2018 and 2026
  • Figure 57 : Latin America Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2018–2026
  • Figure 58 : Latin America Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
  • Figure 59 : Latin America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018-2026
  • Figure 60 : Middle East & Africa Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, 2016–2026
  • Figure 61 : Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
  • Figure 62 : Middle East & Africa Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
  • Figure 63 : Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share Analysis, by Type, 2018 and 2026
  • Figure 64 : Middle East & Africa Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Type, 2018–2026
  • Figure 65 : Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2018 and 2026
  • Figure 66 : Middle East & Africa Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2018–2026
  • Figure 67 : Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
  • Figure 68 : Middle East & Africa Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018–2026
  • Figure 69 : Global Acute Lymphoblastic Leukemia Market Share, by Company, 2017
  • Figure 70 : Pfizer, Inc.’s Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
  • Figure 71 : Pfizer, Inc.’s Oncology Business Segment Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2017
  • Figure 72 : Pfizer, Inc.’s Revenue Share (%), by Business Segment, 2017
  • Figure 73 : Pfizer, Inc.’s Revenue Share (%), by Region, 2017
  • Figure 74 : Novartis AG’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
  • Figure 75 : Novartis AG’s Oncology Business Segment Revenue (US$ Mn) & Y-o-Y Growth (%), 2015–2017
  • Figure 76 : Novartis AG’s Net Sales (%), by Business Segment, 2017
  • Figure 77 : Novartis AG’s Net Sales (%), by Region, 2017
  • Figure 78 : F. Hoffmann-La Roche Ltd.’s, Oncology Segment, Revenue (US$ Bn), 2015–2017
  • Figure 79 : F. Hoffmann-La Roche Ltd.’s Pharmaceutical Segment R&D Expenditure (US$ Bn), 2015–2017
  • Figure 80 : F. Hoffmann-La Roche Ltd.’s Pharmaceutical Segment Revenue (%), by Specialty (2017)
  • Figure 81 : F. Hoffmann-La Roche Ltd.’s Pharmaceutical Segment Revenue (%), by Region (2017)
  • Figure 82 : Sanofi’s Revenue (US$ Bn), 2014?2017
  • Figure 83 : Sanofi’s Regional Sales Breakdown (%), 2017
  • Figure 84 : CELGENE CORPORATION Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
  • Figure 85 : CELGENE CORPORATION Marketing & Sales and R&D Expenses (%), 2015–2017
  • Figure 86 : CELGENE CORPORATION Breakdown of Net Sales (%), by Business Segment, 2017
  • Figure 87 : CELGENE CORPORATION Breakdown of Net Sales (%), by Region, 2017
  • Figure 88 : Amgen, Inc. Marketing & Sales and R&D Expenses (%), 2015–2017
  • Figure 89 : Amgen, Inc. Breakdown of Net Sales (%), by Region, 2017
  • Figure 90 : Amgen, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
  • Figure 91 : Bristol-Myers Squibb Company Revenue (US$ Bn), 2014-2017
  • Figure 92 : Bristol-Myers Squibb Company R&D Expenditure (US$ Bn), 2015- 2017
  • Figure 93 : Bristol-Myers Squibb Company Revenue, by Geography, 2017
  • Figure 94 : Spectrum Pharmaceuticals, Inc. Revenue (US$ Mn), 2015- 2017
  • Figure 95 : Spectrum Pharmaceuticals, Inc. R&D Expenditure (US$ Mn), 2014-2017

Leaders in analytics, research and advisory services for Fortune 500 companies, scores of high potential startups, and financial institutions. Our success stories have proven why we are a prominent provider of a cutting-edge syndicated and customized research services. Leverage the best of our seasoned research analysts who had a keen interest and enviable expertise of almost 4 million hours in global, regional, and local market intelligence.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
RELATED REPORTS